Purchase this article with an account.
R. P. Conley, M. K. Shah, G. Thompson, W. Perez, J. A. Seedor, D. C. Ritterband; A Comparison of the in-vitro Susceptibility Profile of Ceftobiprole Against Methicillin Resistant Staphylococcus aureus (MRSA) Ocular Isolates. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5711.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the in-vitro susceptibility profiles of ceftobiprole, a novel 5th generation cephalosporin against ocular isolates of Methicillin Resistant Staph aureus (MRSA).
15 MRSA, 3 Methicillin Sensitive Staph aureus (MSSA), 3 Staph epidermidis, 1 Strep viridans group, and 1 each of Serratia marcescens, Haemophilus influenzae, and Pseudomonas aeruginosa isolates from cases of corneal ulcers were tested for in vitro susceptibility against ceftobiprole, moxifloxacin, gatifloxacin, gentamicin, and vancomycin using a Kirby Bauer method.
Ceftobiprole was active against all 15 MRSA strains tested with zones of inhibition ranging from (18 to 38 mm). Moxifloxacin and Gatifloxacin had 8/15 resistant and 10/15 resistant MRSA strains respectively. Gentamicin had 3/15 resistant MRSA organisms. All 15 MRSA strains were sensitive to vancomycin. In addition ceftobiprole was active against all the other isolates.
Ceftobiprole is the first of a new class of broad-spectrum anti-MSRA cephalosporins with activity against methicillin-resistant Staphylococcus aureus and gram negative organisms. With increasing concern of resistance among MRSA ocular isolates to currently available antimicrobials ceftobiprole may be a promising new therapeutic alternative.
This PDF is available to Subscribers Only